ClearPoint Neuro/$CLPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ClearPoint Neuro
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Ticker
$CLPT
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
115
ISIN
US18507C1036
Website
ClearPoint Neuro Metrics
BasicAdvanced
$318M
-
-$0.75
1.04
-
Price and volume
Market cap
$318M
Beta
1.04
52-week high
$19.22
52-week low
$5.11
Average daily volume
309K
Financial strength
Current ratio
3.527
Quick ratio
2.336
Long term debt to equity
14.309
Total debt to equity
17.201
Profitability
EBITDA (TTM)
-20.853
Gross margin (TTM)
61.20%
Net profit margin (TTM)
-64.51%
Operating margin (TTM)
-67.29%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-32.39%
Return on equity (TTM)
-76.21%
Valuation
Price to revenue (TTM)
9.63
Price to book
15.75
Price to tangible book (TTM)
16.12
Price to free cash flow (TTM)
-26.443
Free cash flow yield (TTM)
-3.78%
Free cash flow per share (TTM)
-42.54%
Growth
Revenue change (TTM)
23.22%
Earnings per share change (TTM)
-9.31%
3-year revenue growth (CAGR)
23.05%
10-year revenue growth (CAGR)
23.86%
3-year earnings per share growth (CAGR)
1.46%
10-year earnings per share growth (CAGR)
-20.00%
What the Analysts think about ClearPoint Neuro
Analyst ratings (Buy, Hold, Sell) for ClearPoint Neuro stock.
Bulls say / Bears say
Lake Street Capital raised its price target for ClearPoint Neuro from $17.00 to $30.00, maintaining a 'buy' rating, indicating strong confidence in the company's growth prospects. (americanbankingnews.com)
Stifel Nicolaus increased its price target for ClearPoint Neuro from $19.00 to $25.00, reflecting optimism about the company's future performance. (webull.com)
ClearPoint Neuro achieved record revenue and a 41% year-over-year growth in Q3 2024, demonstrating strong operational performance. (siriusinvestors.com)
ClearPoint Neuro reported a quarterly loss of $0.18 per share in Q3 2024, missing the consensus estimate of a loss of $0.17, which may raise concerns about profitability. (siriusinvestors.com)
The company's stock reacted negatively to its Q3 2024 earnings report, possibly due to its high valuation and weak sequential growth, indicating potential volatility. (siriusinvestors.com)
Despite revenue growth, ClearPoint Neuro's negative net margin of 59.64% and negative return on equity of 62.10% in Q3 2024 highlight ongoing financial challenges. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
ClearPoint Neuro Financial Performance
Revenues and expenses
ClearPoint Neuro Earnings Performance
Company profitability
ClearPoint Neuro News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ClearPoint Neuro stock?
ClearPoint Neuro (CLPT) has a market cap of $318M as of June 20, 2025.
What is the P/E ratio for ClearPoint Neuro stock?
The price to earnings (P/E) ratio for ClearPoint Neuro (CLPT) stock is 0 as of June 20, 2025.
Does ClearPoint Neuro stock pay dividends?
No, ClearPoint Neuro (CLPT) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next ClearPoint Neuro dividend payment date?
ClearPoint Neuro (CLPT) stock does not pay dividends to its shareholders.
What is the beta indicator for ClearPoint Neuro?
ClearPoint Neuro (CLPT) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.